title: Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity.
abstract: To enhance the selective delivery of antitumor drugs into regional lymph nodes and cancerous tissues via a hyaluronate (HA) receptor (CD44), we synthesized HA-mitomycin C complex and HA-epirubicin complex. To investigate the specific distribution of HA into regional lymph nodes and to evaluate the HA receptor on lewis lung carcinoma cells, we also synthesized 14C-labelled HA and fluorescent HA (FR-HA). The metabolic studies of 14C-HA and HA-epirubicin complex were performed in rats. The specific distribution of both compounds to the lymph nodes were observed after sc treatment. Internalization mechanisms of HA into carcinoma cells (lewis lung carcinoma) via HA receptor was investigated using fluorescent HA (FR-HA) in vitro. Internalization of FR-HA following binding to the cell surfaces was observed. HA-Mitomycin C (MMC) exhibited potent anti-metastatic effects against lewis lung carcinoma implanted in mice at an extremely low dose (0.01 mg/kg) whereas free MMC had no effects.
authors.affiliation: Department of Pharmaceutics, Research Center, Shiseido Corporation, Yokohama, Kanagawa, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Akima
authors.forename: H
authors.initials: H
authors.lastname: Ito
authors.forename: Y
authors.initials: Y
authors.lastname: Iwata
authors.forename: K
authors.initials: K
authors.lastname: Matsuo
authors.forename: N
authors.initials: N
authors.lastname: Watari
authors.forename: M
authors.initials: M
authors.lastname: Yanagi
authors.forename: H
authors.initials: H
authors.lastname: Hagi
authors.forename: K
authors.initials: K
authors.lastname: Oshima
authors.forename: A
authors.initials: A
authors.lastname: Yagita
authors.forename: Y
authors.initials: Y
authors.lastname: Atomi
authors.forename: I
authors.initials: I
authors.lastname: Tatekawa
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D004338:Drug Combinations; D004354:Drug Screening Assays, Antitumor; D015251:Epirubicin / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D018960:Hyaluronan Receptors / Q000378:metabolism; D006820:Hyaluronic Acid / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D016685:Mitomycin / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured
chemical_list: D000903:Antibiotics, Antineoplastic; D004338:Drug Combinations; D018960:Hyaluronan Receptors; D015251:Epirubicin; D016685:Mitomycin; D006820:Hyaluronic Acid